Roche: The US and Asia outsprint Europe in life science sector

Slow regulatory processes and an unwillingness to pay the price for new medicines are contributing factors to Europe losing its significance as the home of drug development, criticizes Roche CEO.

Europe risks losing the race to win the favor of pharmaceutical companies, CEO at Roche Severin Schwan tells business daily Børsen.

He highlights easier access to health data and a willingness to reward innovation as deciding factors in explaining why the US and Asia are surpassing Europe in the pharmaceutical industry.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs